Relationships between serotoninergic system and skin fibrotic

Antiinflamm Antiallergy Agents Med Chem. 2014 Mar;13(1):9-16. doi: 10.2174/18715230113129990018.

Abstract

Cutaneous fibrosis seen in systemic sclerosis (SSc) is a generalized connective tissue disorder, characterized by a wide spectrum of microvascular and immunological abnormalities. Serotonin (5-hydroxytryptamine; 5-HT) is a neurotransmitter and immune modulator, is also an important mediator of bidirectional interactions between the vasoactive amines and the skin.5-HT, a commonly secreted amine, is a known inducer of fibrosis, although the mechanistic basis for it and growth factors regulating fibrosis and proliferation in the microenvironment are unclear. We review that as serotonin has powerful vasodilator, immunomodulator, and growth factor actions, this pathway could be involved in skin fibrotic. Since serotoninergic system play a role in skin fibrotic, and 5-HTs drugs, an usual treatment for this type of patients. These provides a future perspective for research and drug development.

Publication types

  • Review

MeSH terms

  • Animals
  • Cell Growth Processes / drug effects
  • Dopamine Agonists / therapeutic use*
  • Fibrosis
  • Humans
  • Lisuride / analogs & derivatives*
  • Lisuride / therapeutic use
  • Precision Medicine
  • Receptor, Serotonin, 5-HT1A / metabolism
  • Scleroderma, Systemic / drug therapy*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Serotonin / metabolism*
  • Skin / drug effects
  • Skin / pathology*

Substances

  • Dopamine Agonists
  • Serotonin Uptake Inhibitors
  • Receptor, Serotonin, 5-HT1A
  • dironyl
  • Serotonin
  • Lisuride